Gentian Diagnostics ASOSL:GENT -2.04%74 Return-on-Tangible-Equity is 9.87% as of Jun. 2026. GuruFocus rates OSL:GENT with a GF Score™ of 74/100 and a GF Value™ of kr59.17 (Significantly Undervalued). Among 760 Medical Devices & Instruments companies, Gentian Diagnostics AS ranks worse than 63.95% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Gentian Diagnostics AS's annualized net income for the quarter that ended in Jun. 2026 was kr17.7 Mil. Gentian Diagnostics AS's average shareholder tangible equity for the quarter that ended in Jun. 2026 was kr179.2 Mil. Therefore, Gentian Diagnostics AS's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 9.87%.
The historical rank and industry rank for Gentian Diagnostics AS's Return-on-Tangible-Equity or its related term are showing as below:
OSL:GENT'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -19.33 Med: -10.57 Max: 31.12
Current: -4.87
During the past 13 years, Gentian Diagnostics AS's highest Return-on-Tangible-Equity was 31.12%. The lowest was -19.33%. And the median was -10.57%.
OSL:GENT's Return-on-Tangible-Equity is ranked worse than 63.95% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.03
vs OSL:GENT: -4.87
Gentian Diagnostics AS (OSL:GENT) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Gentian Diagnostics AS Return-on-Tangible-Equity Related Terms
Gentian Diagnostics AS Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Gentian Diagnostics AS's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS Return-on-Tangible-Equity Chart
OSL:GENT vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Gentian Diagnostics AS's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 9.87% mean?
Gentian Diagnostics AS (OSL:GENT) has a Return-on-Tangible-Equity of 9.87% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Gentian Diagnostics AS and its competitors. According to the industry distribution chart, Gentian Diagnostics AS ranks #486 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 63.9%.
Is Gentian Diagnostics AS's Return-on-Tangible-Equity too high?
Gentian Diagnostics AS's current Return-on-Tangible-Equity is 9.87%. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.03. Gentian Diagnostics AS's value of 9.87% is 144.9% above this industry median. Based on the distribution chart, Gentian Diagnostics AS ranks #486 out of 760 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Gentian Diagnostics AS has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #486 out of 760 companies for Return-on-Tangible-Equity. This places Gentian Diagnostics AS in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.03. Gentian Diagnostics AS's value of 9.87% is 144.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.03, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gentian Diagnostics AS's current Return-on-Tangible-Equity of 9.87% is 144.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Gentian Diagnostics AS and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gentian Diagnostics AS's current Return-on-Tangible-Equity is 9.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Significantly Undervalued. The stock's GF Value™ is kr59.17, compared to a current price of kr38.40 — trading 35.1% below its estimated fair value. The current Return-on-Tangible-Equity is 9.87% and 144.9% above the Medical Devices & Instruments industry median of 4.03. Gentian Diagnostics AS's overall GF Score™ is 74/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current Return-on-Tangible-Equity is 9.87% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of kr38.40 is trading 35.1% below its estimated GF Value™ of kr59.17.
GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.
Key valuation signals for OSL:GENT:
Return-on-Tangible-Equity: 9.87%
GF Value™: kr59.17 vs. price of kr38.40 (35.1% below fair value)
Industry Position: 144.9% above the Medical Devices & Instruments median (#486 of 760)
No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
74GF Score
Get the complete analysis for OSL:GENT
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:GENT has been successfully added to your 
